Authors : Ahmed Abdul Bari Hazari
DOI : 10.18231/j.ijpp.2020.022
Volume : 7
Issue : 2
Year : 2020
Page No : 130-135
Background: Chronic Obstructive Pulmonary Disease affects more than 15 million Americans, with the
majority of the patients more than 50 years old with current or past smokers.
Objective: To study the safety and efficacy of Tiotropium bromide inhalation in both COPD & Bronchial
Asthma patients.
Materials and Methods: The present study was conducted in patients with stable as well as exacerbated
COPD and Br. Asthma at Shadan Hospital, Telangana.
Results: Significant improvement in Forced expiratory volume with respect to baseline at the end of the
14th week. The maximum mean response in FEV1 improved by 0.221, (68.03%) when the compared value
of baseline 0.13L (p-value < 0>
compared to COPD treatment group. The Forced expiratory volume (FEV1), Forced vital capacity (FVC)
and FEV1/FVC ratio were improved with respect to baseline.
Conclusion: Tiotropium via dry powder inhaler result in 24 hr bronchodilation as well as consistent and
sustained improvement for both the COPD and the Bronchial Asthma patients.
Keywords: Bronchial asthma, COPD, FEV1, FVC, FEV1/FVC ratio.